regulatory
confidence high
sentiment negative
materiality 0.60
Aprea Therapeutics receives Nasdaq extension to Jan 19, 2027 to regain $1 minimum bid price compliance
Aprea Therapeutics, Inc.
- Received Nasdaq notification on July 23, 2026 granting additional 180-day compliance period until Jan 19, 2027.
- Must achieve closing bid price of $1.00 for 10 consecutive business days during extension.
- If not compliant by Jan 19, 2027, Nasdaq will issue delisting notice; company may appeal.
- Previously reported deficiency notice on Jan 23, 2026; initial 180-day period expired July 22, 2026.